Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In 2021 I look forward to the approval of all 3 Covid tests; all 3 delivery forms of 2020; all 3 uses of Abivirtinib; all 3 applications of RTX; and all 3 non-opioid pain treatments. In 2021 we will start to see the payoff of the SmartPharm , ACEA and Mayo Clinic technology acquisitions. And 2021 will see half a dozen EUA's, settlement of the PSS lawsuit, maturation of the Celularity and ImmunityBio investments, and several large government grants and the beginning of large scale cash flow.
Everyone should read carefully the Transcript of the January 20, 2021 Riley Oncology Conference. It is loaded with important information for investors.
https://seekingalpha.com/article/4400090-sorrento-therapeutics-inc-srne-ceo-henry-ji-presents-b-riley-virtual-oncology-conference?utm_source=dowjonesnewswire.com&utm_medium=referral
Transcript of the January 20, 2021 Riley Oncology Conference. Loaded with important information for investors.
https://seekingalpha.com/article/4400090-sorrento-therapeutics-inc-srne-ceo-henry-ji-presents-b-riley-virtual-oncology-conference?utm_source=dowjonesnewswire.com&utm_medium=referral
I recommend this be a sticky.
Covi-MSC is only one of 8 potential Covid Emergency Use Authorization candidates...all Blockbusters!
1. Covi-Stix rapid accurate virus test
2. Covi-Track rapid accurate antibody test
3. Covi-push 2020 injection
4. Covi-Drops 2020 nose drops
5. Covi-Vax 2020 lipid DNA injection
6. Abivirtinib ARDS prevention
7. Covi-MSC Stem Cell ARDS treatment
8. Covi-Shield antibody cocktail
Each of these EUA's could be accompanied by Operation Warp Speed grants and multi-billion dollar international sales. Additionally there could multi-billion dollar worldwide marketing partnerships. Dr.Ji says there is interest from Mexico, Brazil and Europe.
Timing? Some could come in days. Some in weeks. Others in several months.
In addition to these 8 Covid EUA candidates Sorrento has other potential multi $Billion programs ... here are 2 samples from each of the three portfolio areas...with at least 4 with 2021 revenue potential!
NON-OPIOID PAIN
1. SP-102 phase 3 over 90% enrolled, fast track, lumbar/sciatic pain
2. RTX intractable cancer, knee and arthritic pain
COVID
1. rapid, accurate, low cost tests. TRACK, TRACE, STIX
2. 2020 DROPS, injection and plasmid DNA
CANCER
1. Abivirtinib NSCLC phase 3, lymphomas phase 2, prostate IND, lupus
2. SmartPharm plasmid DNA Plus DAR-T and Mayo Clinic ADNIC drugs.
Do your dd and have a look at the January 2021 presentation. There are several more potential blockbusters IMO!
https://investors.sorrentotherapeutics.com/static-files/c7e5a3a2-7849-42e7-b531-2e6a7a7f3e94
In addition to their stem cell program Sorrento has SIX other potential multi $Billion programs ... here are 2 from each of the three portfolio areas...with at least 4 with 2021 revenue potential!
NON-OPIOID PAIN
1. SP-102 phase 3 over 90% enrolled, fast track, lumbar/sciatic pain
2. RTX intractable cancer, knee and arthritic pain
COVID
1. rapid, accurate, low cost tests. TRACK, TRACE, STIX
2. 2020 DROPS, injection and plasmid DNA
CANCER
1. Abivirtinib NSCLC phase 3, lymphomas phase 2, prostate IND, lupus
2. SmartPharm plasmid DNA Plus DAR-T and Mayo Clinic drugs.
Keep this in mind as you enjoy the January 2021 presentation.There are several more IMO!
https://investors.sorrentotherapeutics.com/static-files/c7e5a3a2-7849-42e7-b531-2e6a7a7f3e94
A scientific article about why your belly fact stem cells might be useful!
Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients
Christopher J. Rogers1*, Robert J. Harman1, Bruce A. Bunnell2, Martin A. Schreiber3, Charlie Xiang4, Fu-Sheng Wang5, Antonio F. Santidrian6 and Boris R. Minev6,7
Abstract
In late 2019, a novel coronavirus (SARS-CoV-2) emerged in Wuhan, capital city of Hubei province in China. Cases of SARS-CoV-2 infection quickly grew by several thousand per day. Less than 100 days later, the World Health Organiza-tion declared that the rapidly spreading viral outbreak had become a global pandemic. Coronavirus disease 2019 (COVID-19) is typically associated with fever and respiratory symptoms. It often progresses to severe respiratory distress and multi-organ failure which carry a high mortality rate. Older patients or those with medical comorbidi-ties are at greater risk for severe disease. Inflammation, pulmonary edema and an over-reactive immune response can lead to hypoxia, respiratory distress and lung damage. Mesenchymal stromal/stem cells (MSCs) possess potent and broad-ranging immunomodulatory activities. Multiple in vivo studies in animal models and ex vivo human lung models have demonstrated the MSC’s impressive capacity to inhibit lung damage, reduce inflammation, dampen immune responses and aid with alveolar fluid clearance. Additionally, MSCs produce molecules that are antimicrobial and reduce pain. Upon administration by the intravenous route, the cells travel directly to the lungs where the majority are sequestered, a great benefit for the treatment of pulmonary disease. The in vivo safety of local and intravenous administration of MSCs has been demonstrated in multiple human clinical trials, including studies of acute respiratory distress syndrome (ARDS). Recently, the application of MSCs in the context of ongoing COVID-19 disease and other viral respiratory illnesses has demonstrated reduced patient mortality and, in some cases, improved long-term pulmonary function. Adipose-derived stem cells (ASC), an abundant type of MSC, are proposed as a therapeutic option for the treatment of COVID-19 in order to reduce morbidity and mortality. Additionally, when proven to be safe and effective, ASC treatments may reduce the demand on critical hospital resources. The ongoing COVID-19 outbreak has resulted in significant healthcare and socioeconomic burdens across the globe. There is a desperate need for safe and effective treatments. Cellular based therapies hold great promise for the treatment of COVID-19. This literature summary reviews the scientific rationale and need for clinical studies of adipose-derived stem cells and other types of mesenchymal stem cells in the treatment of patients who suffer with COVID-19.Keywords:COVID-19, SARS-CoV-2, ARDS, Pneumonia, Mesenchymal stem cells
Here's some background on the stem cell trial we heard about today.
COVID-19 Stem cell trial Clinical Trial info from the PSC website.
Sorrento Therapeutics, Inc. has licensed this program and is conducting this clinical trial (www.sorrentotherapeutics.com)
Personalized Stem Cells(PSC) COVID-19 clinical trial
"Coronavirus disease (COVID-19) is a global pandemic that is threatening the health and welfare of the entire world. Treatment options are needed now. The White House Coronavirus Task Force asked PSC to file for accelerated FDA approval for our first study, for COVID-19. We immediately submitted our FDA request and received FDA approval quickly.
Why Stem Cells for COVID-19?
Stem cell therapy is one of the few approaches that directly treats the lung inflammation of the most serious COVID-19 patients
Recent publications report strikingly positive outcomes from treating COVID-19 patients with stem cells (China, Israel)
Published studies show reduction in death loss and reduced ventilator need. PSC has FDA-inspected stem cell manufacturing facilities already producing stem cells
COVID-19 Clinical Trial
This first study is only in a single hospital in California and limited to 20 serious patients. Please do not request enrollment information at this time as the limited enrollment will be done at the hospital from existing hospitalized COVID-19 patients.
Clinical Trial Design
20 patient Phase 1 study – one hospital
IV treatment of hospitalized serious COVID-19 patients
Stem cells are from disease-screened donors manufactured in FDA facilities
Three doses will be given over several days by simple IV infusion
86-day study – measures reduction in days in the ICU, reduction in ventilator use, safety, lung function
Enrollment planned to begin in August"
NOTE THAT THE TRIAL WHICH PSC PLANNED TO START IN AUGUST 2021 WAS ADVANCED TO JANUARY BY SORRENTO! Dr.Ji has said only 40 patients might be needed to receive an EUA. Enrollment should be rapid!
This news about the first 4 ARDS patients is very important. There is a potential EUA here! More patients needed but enrollment should be rapid! This is #7 on the list I posted earlier today. There's a lot of good news coming.
8 potential Emergency Use Authentication candidates...all Blockbusters!
1. Covi-Stix rapid accurate virus test
2. Covi-Track rapid accurate antibody test
3. Covi-push 2020 injection
4. Covi-Drops 2020 nose drops
5. Covi-Vax 2020 lipid DNA injection
6. Abivirtinib ARDS prevention
7. Stem Cell ARDS treatment
8. Covi-Shield antibody cocktail
Each of these EUA's could be accompanied by Operation Warp Speed grants and multi-billion dollar international sales. Additionally there could multi-billion dollar worldwide marketing partnerships.
Timing? Some could come in days. Some in weeks. Others in several months.
And don't forget the pain and cancer portfolios! RTX and Sp-102 are potential pain blockbusters. So are Abivirtinib , the Mayo ADNIC technology and DAR-T in cancer! Lots of news coming ...and news drives the share price!
What you are looking for is acea therapeutics.
8 potential Emergency Use Authentication candidates...all Blockbusters!
1. Covi-Stix rapid accurate virus test
2. Covi-Track rapid accurate antibody test
3. Covi-push 2020 injection
4. Covi-Drops 2020 nose drops
5. Covi-Vax 2020 lipid DNA injection
6. Abivirtinib ARDS prevention
7. Stem Cell ARDS treatment
8. Covi-Shield antibody cocktail
Each of these EUA's could be accompanied by Operation Warp Speed grants and multi-billion dollar international sales. Additionally there could multi-billion dollar worldwide marketing partnerships.
Timing? Some could come in days. Some in weeks. Others in several months.
I like this brief overview !
" I’m looking at all the individual pieces, shares in other companies, etc... and Sorrento is extremely undervalued. Through IPO’s, cash on hand, selling of stock if need to as well though I have my doubts Sorrento will, to move their trials forward. SP102 and Abivertinib trials will be off the board with approvals, and bring in revenue sometime later this year most likely. 2020/2099 and GeneMab will be bankrolled by government contracts and grants. That’s what Ji is waiting for and will get. Some people will say he should have concentrated on moving forward just a few trials to become profitable, but that’s not Ji’s mindset. The average investor wants a quick turnaround. Ji saw the chance to quickly move forward trials that would normally have taken many years, but for the coronavirus. He’s building a small Pharma or a large biotech. He’s after bigger game then just a couple billion in his bank, and retirement. Some people are built differently. The SP will be a lot higher when their shares in ImmunityBio/NK and Celularity/GXGX hit the market. A lot to look forward to with pleasure this year."
Sorrento has the largest Covid portfolio in the world! This is important because the pandemic is worldwide and has dragged down economies around the world. The key to economic recovery is defeating Covid around the world. There will be worldwide demand for many Sorrento products. Clearly the Sorrento share price will increase dramatically as these products reach their worldwide market.
But the Sorrento share price will be influenced by the overall stock market. Just as all boats rise in a rising market...all boats can drift down in a sinking market. Why do I think the US stock market will rise and thereby benefit Sorrento? The answer is that America needs a massive infrastructure rebuilding program. I consider this to be an obvious fact that will receive bipartisan support! China, Japan and much of Europe have better roads, bridges, railroads and airports than the US. I know this because I have been there and seen them for myself. I hope to see a massive bipartisan infrastructure program creating millions of high paying jobs!
That will boost the economy.
That will boost the stock market.
That will that produce an encouraging context for Sorrento's success!
All columnists are somebodies hacks! But is the data wrong? Do you know of a better, more accurate analysis? I always try to invest based on solid data.
I spent some time as a research economist, and I also would like us all, despite political differences to prosper in our investments...so I found this information both interesting and encouraging.
Yahoo Finance
How the stock market and economy performed under Democratic presidents
Brian Sozzi·Editor-at-Large
Wed, January 20, 2021, 4:31 AM
Inauguration Day for President-elect Joe Biden couldn’t get here quick enough for stock market bulls (and let’s face it, civilization at large).
Because according to historical data, stocks tend to do very well in the early goings of a Democratic presidency. In year one of a Democratic presidency, the S&P 500 has risen on average by 19.4% dating back to 1932, per data crunched by BMO Capital Markets chief markets strategist Brian Belski.
The gains have tended to stretch throughout the presidency of Democrats, Belski’s data shows. On average, the S&P 500 has gained 10.4% annually when a Democrat has been in office compared to a 6.6% return under Republican leadership. The S&P 500 has performed better in down years, too, when Democrats are in the Oval Office — the average annual decline has been 9.5% versus a 13.9% drop for a Republican leader."
The first approval for an EUA is probably for COVI-STIX. Sorrento does not control the regulatory agencies in the US or Mexico but we know COVI-STIX is being mass produced and test results have been submitted in both countries. In his Riley presentation Dr. Ji said they expect a response "soon". He said the international demand for the product from Europe, Brazil and Mexico is "humongous"! Sales will be in the billions IMO.
Covi-Track could also be very close to approval.
Interestingly in the same talk he said COVI-PUSH phase 1 would finish "momentarily". A combined phase 2/3 would not take long.
And he said the company expects "...a quick response..."for COVI-DROPS.
And the 40 patient interim results from Abivirtinib to prevent and treat ARDS is very close. And with very encouraging Stem Cell results that drug might also be approvable with 40 patients according to Dr.Ji.
Some tests might be approved as early as next week.
Some drugs might be approved as early as next month.
No-one on this board knows. But I'll go with science...it looks good! No other Biopharm company has this many shots on goal.
There are 6 or 7 potential Sorrento Covid EUA's. The first could come next week. Several in the next month. EUA's can, and have, been granted on the basis of phase 1 and/or phase 2 results. Each Sorrento Covid EUA is worth billions in revenue! Just the first one will blow the shorts out of the water!
Some Covid monoclonal antibodies have received an EUA on the basis of a phase 1 or phase 2 trial. Is this unheard of? No, in fact many cancer drugs have received accellerated approval on the same basis.
"Nature published a study in 2016 titled The Impact of Breakthrough Therapy Designation on Cancer Drug Development
Of the 12 approved oncology drugs with breakthrough designation, 8 (66%) were approved based on Phase I or Phase II data. By contrast, 4 of 17 (24%) of drugs without breakthrough designation were approved on the basis of Phase II data, and none on the basis of Phase I data (Fig. 1c)."
Just as cancer is a life threatening disease, so is Covid. Sorrento has several Covid drugs which could receive EUA's based on phase 1 or 2 trial results!
Fintel says Institutions now own 42% of Sorrento. They owned about 14 % when I first bought earlier this year. They list Dr. Ji holding about 6% of the company...but of couse he has options and incentives. Clearly his interests are aligned with shareholders! When the tutes decide to move the share price...it will move bigtime! Hold on.
I think the $35 target is dramatically underestimating all three areas of Sorrento's pipeline! I think Sorrento will have several Covid blockbusters in the market in coming months. RTX and SP102 will be blockbusters. And Abivirtinib approval in several cancer indications will certainly be a blockbuster. And DAR-T and ADNIC have equally enormous potential. IMO Sorrento will soon hit the $35 range and triple digits with several coming EUA's! Sorrento has the world's largest Covid pipeline...and this worldwide pandemic is far from over!
Alliance Global initiated coverage today with. Listed as a BUY. Target is $35
We are initiating coverage of Sorrento Therapeutics (SRNE) with a Buy rating and
a $35 price target. SRNE combines one of the most active and promising pipelines
in the COVID space with a potentially transformative non-opioid pain pipeline, and
adds in a deep oncology pipeline. Most of SRNE's pipeline has significant catalysts
over the next 1-4 quarters, with multiple late stage clinical data read-outs and multiple
potential Emergency Use Authorization (EUA) launches as well. In their COVID pipeline
SRNE has 3 focus areas: 1) Diagnostics - with 2 accurate rapid-turnaround antigen and
antibody tests; 2) Therapeutics - with multiple monoclonal antibody (mAbs) neutralizing
antibodies and a 3-mAb cocktail in development to target potential mutations; and 3)
Rescue Treatments - with a re-purposed oncology compound for Acute Respiratory
Distress Syndrome (ARDS) COVID patients, and a BTK inhibitor also to treat ARDS. In
their pain portfolio SRNE has 2 novel non-opioid pain compounds targeting 3 separate
pain states in osteoarthritis (OA) pain, cancer pain, and sciatica pain that could each
help dramatically reduce the overuse of ineffective and addictive long-acting opioids. In
their immuno-oncology pipeline SRNE has multiple late stage shots on goal including
Abivertinib for NSCLC & B-cell lymphomas with Phase 3 data in 1H21, as well as a
next generation DAR-T platform for multiple myeloma and an oncolytic virus platform
for solid tumors. We are initiating coverage with a Buy rating and a $35 price target
based on a sum-of-the-parts, primarily based on our expectations for the company's
COVID pipeline. We value SRNE's COVID pipeline at $21.50/share altogether, the nonopioid
pain pipeline at $6/share altogether, and the Immuno-oncology pipeline at $4.50/
share altogether. We value the remaining assets and cash, less long term debt (end
'22E) at $3/share for our $35 price target.
Transcript of the January 20, 2021 Riley Oncology Conference. Loaded with important information for investors.
https://seekingalpha.com/article/4400090-sorrento-therapeutics-inc-srne-ceo-henry-ji-presents-b-riley-virtual-oncology-conference?utm_source=dowjonesnewswire.com&utm_medium=referral
I recommend this be a sticky.
We haven't heard much about the Mayo clinic ADNIC technology until today. All I can is WOW! If you listen to the presentation at the 22:30 mark and following, Dr.Ji describes the multi-modal combination BOMB that is guided to the cancer site to attack the cancer in several ways at once. The attack could combine several of the following...
* antibodies
* Abraxane
* Avastin
* anti-PD-1
* cytokines(eg. IL-2)
* an ADC(eg. CD 38)
* NK cells
This unique technology is protected by about 200 worldwide patents. Potential revenue? Multi-billions IMO! Listen after 22:30
https://www.webcaster4.com/Player/Index?webcastId=39569&g=e319a007-37e0-4ca7-99c2-592072e1500d&uid=6045072&sid=
The ICU's are overflowing. Enrollment in the stem cell trial just started. As news of very sick patients in the ICU being treated successfully , their lives saved, and going home....enrollment will be very rapid! The people being treated are very ill. A CRO is handling the enrollment. PSC was going to start this trial in August, 6 months from now. Thank God Sorrento licenced this technology...lives are already being saved! No wonder Dr. Ji is excited!
I heard the entire presentation...it is worth a listen. I know many are interested in Sorrento's stem cell treatment for severely ill ICU patients. Dr. Ji said the third patient has just been dosed. The first two responded to treatment and have been released from hospital! That's very good news!
https://www.webcaster4.com/Webcast/Page/2433/39569
VERY impressive presentation! Loads of information! Multi-billion revenues this year IMO!
https://www.webcaster4.com/Webcast/Page/2433/39569
Something to think about.
"Let’s discount the fact that Abivertinib (NSCLC) and SP102 will be approved and on the market later on this year.
There is a difference between EUA and FDA approvals. EUA approvals have been given for drugs after just phase 2. Two examples are Lilly’s and Regeneron’s therapeutics which are proven to not be as potent as Sorrento’s. EUA’ approvals move the SP needle. ACEA buyout will move the needle. Contracts, grants and partnerships will move the needle. Ji may not be a good oral speaker when trying to connect with the average retail investor, but let’s look at his track record. He has managed to move trials, expand Sorrento’s pipeline, and make deals without selling piecemeal to big pharma. The science community trusts Ji, and Sorrento’s science enough to in some cases take stock instead of cash to close a business deal. Look how that benefited both Sorrento and SmartPharm. DARPA contract, and with that confirmation on the science.
I expect government contracts on condition of EUA approval for both 2020 and Abivertinib (covid). That’s not even including Sorrento’s EUA application for STIX. Please note that Moderna among other companies were given 1B+ contracts while still in Phase 1 on the condition of EUA approval. Look back at how high the SP needle moved for Moderna while still in phase 1 soon afterwards."
Wednesdays Fireside Chat is an Oncology conference. We have not had an update on Sorrento's cancer portfolio for a long time. Abivertinib in cancer, Dar-T program and the Mayo Clinic ADNIC program updates as well a pancreatic trial would be of interest. Of course an EUA or two in the Covid program would also be welcome news.
I find this troubling. I would prefer a 2020 shot!
Norway Raises Concern Over Vaccine Jabs for the Elderly
By Lars Erik Taraldsen
January 16, 2021, 6:06 AM PST Updated on January 16, 2021, 3:45 PM PST
Death count raised, age threshold lowered from initial report.Country suggests vaccines may be too risky for the elderly
Norway expressed increasing concern about the safety of the Pfizer Inc. vaccine on elderly people with serious underlying health conditions after raising an estimate of the number who died after receiving inoculations to 29.
The latest figure adds six to the number of known fatalities in Norway, and lowers the age group thought to be affected to 75 from 80. While it’s unclear exactly when the deaths occurred, Norway has given at least one dose to about 42,000 people and focused on those considered most at risk if they contract the virus, including the elderly.
Until Friday, the vaccine produced by Pfizer and BioNTech SE was the only one available in Norway, and “all deaths are thus linked to this vaccine,” the Norwegian Medicines Agency said in a written response to Bloomberg on Saturday.
“There are 13 deaths that have been assessed, and we are aware of another 16 deaths that are currently being assessed,” the agency said. All the reported deaths related to “elderly people with serious basic disorders,” it said. “Most people have experienced the expected side effects of the vaccine, such as nausea and vomiting, fever, local reactions at the injection site, and worsening of their underlying condition.”
Official reports of allergic reactions have been rare as governments rush to roll out vaccines to try to contain the global pandemic. U.S. authorities reported 21 cases of severe allergic reactions from Dec. 14-23 after administration of about 1.9 million initial doses of the Pfizer vaccine. The first Europe-wide safety report on the Pfizer-BioNTech vaccine is due to be published at the end of January.
Australia’s Concern
Australia, which has an agreement for 10 million doses of the Pfizer vaccine, is seeking urgent information on the issue from the producer, health authorities and Norway’s government, Health Minister Greg Hunt told reporters in Melbourne on Sunday.
Australia’s Therapeutic Goods Administration will seek “additional information, both from the company, but also from the Norwegian medical regulator,” Hunt said. Australia’s foreign ministry will also contact its counterpart in Norway on the issue.
Norway’s experience doesn’t mean that younger, healthier people should avoid being vaccinated. But it’s an early indication of what to watch as countries begin to issue safety monitoring reports on the vaccines. Emer Cooke, the new head of the European Medicines Agency, has said tracking the safety of Covid vaccines, especially those relying on novel technologies such as messenger RNA, would be one of the biggest challenges once shots are rolled out widely.
Though the two Covid-19 vaccines approved so far in Europe were tested in tens of thousands of people -- including volunteers in their late 80s and 90s -- the average trial participant was in his or her early 50s. The first people to be immunized in many places have been older than that as countries rush to inoculate nursing-home residents at high risk from the virus.
Too Risky
The findings have prompted Norway to suggest that Covid-19 vaccines may be too risky for the very old and terminally ill, the most cautious statement yet from a European health authority.
The Norwegian Institute of Public Health judges that “for those with the most severe frailty, even relatively mild vaccine side effects can have serious consequences. For those who have a very short remaining life span anyway, the benefit of the vaccine may be marginal or irrelevant.”
Pfizer and BioNTech are working with the Norwegian regulator to investigate the deaths in Norway, Pfizer said in an e-mailed statement. The agency found that “the number of incidents so far is not alarming, and in line with expectations,” Pfizer said.
“We are aware that deaths have also been reported in other countries, but do not have full details of this yet,” Norway’s medicines agency said. “There are also differences between countries in who is prioritized for vaccination, and this could also affect the reporting of side effects, including death.”
“The Norwegian Medicines Agency has communicated, prior to the vaccination, that when vaccinating the oldest and sickest, it is expected that deaths will occur in a time-related context with vaccination. This does not mean that there is a causal link between vaccination and death. We have also, in connection with the reported deaths, conveyed that it is possible that common and known side effects of the vaccines may have been a contributing factor to a serious course or fatal outcome,” the agency said."
I am intrigued by the stem cell potential. If Abi works against ARDS they might be a powerful combination. Here's someone's summary of the stem cell trial.
"We are obviously hyper focused on pending diagnostics, ACEA, and antibody candidates but let's not forget about COVI-MSC. This could be a sleeper that comes out of nowhere over the next several weeks.
COVI-MSC is another COVID-19 rescue candidate that was licensed from Personalized Stem Cells, Inc. Phase 1 began recruiting on December 15, 2020 with an estimated enrollment of just 20 patients at a single location-- specifically Fresno Community Hospital in California. Initial readout measures are expected at 28 days which we have just passed.
While the study is sponsored by Sorrento, the trials are being managed and executed by VetStem Biopharma Inc. which is a well established and experienced CRO. They also happen to be the parent company of Personalized Stem Cells, Inc. A little skin in the game never hurts!
The potential to add this as a synergistic treatment modality with Abivertinib and/or STI-2020 is very intriguing.
From Sorrento's website on MSC:
"Stem cells have been demonstrated to support resolution of symptoms in multiple disease settings and have the potential to reduce the long-term effects associated with pulmonary tissue damage for these patients. MSC represent a treatment modality with high potential to help in the fight against COVID-19 as a stand-alone therapy or in synergy with other product candidates in Sorrento’s pipeline, including small molecules (abivertinib or salicyn-30) and neutralizing antibodies (STI-1499 or STI 2020)."
https://clinicaltrials.gov/ct2/show/NCT04486001?term=coronastem&draw=2&rank=1
I expect double digits next week and triple digits well before year-end. For me this is not a pump and dump but a real undervalued investment with blockbusters in Covid, cancer and non-opioid pain platforms.
https://investors.sorrentotherapeutics.com/static-files/c7e5a3a2-7849-42e7-b531-2e6a7a7f3e94
FDA finally trying to catch up on monoclonal antibodies. This is Sorrento's strength. Dr. Brunswick has FDA background. Good news for Sorrento .
https://www.fda.gov/media/145128/download
The next two weeks should be fun for longs. I would hate to be short when the market opens Tuesday. 3 big news items coming up. Double digits here we come!
1. ACEA aquisition. Sorrento already has the rights for Abivirtinib outside of China. But the China rights to Abivertinib and worldwide rights to a phase 2 ready lupus drug would be attractive.
2. Interim results of phase 2 trials of Abivirtinib in the US and Brazil in the anti cytokine storm indication. Abivertinib already has some very worthwhile results in Phase 3 against NSCLC and phase 2 against B cell lymphomas. Will it also be useful against cytokine storm caused by Covid, pneumonia , burns etc? Will it receive an EUA?
3. EUA for Covi-Stix in US and Mexico. Rapid, low cost, 98/99% accurate, shallow nasal swab test could fill multi-billion worldwide medical need.
Combined with the growing value of the Celularity and ImmunoBio investments and very likely large settlement of PSS lawsuit...Sorrento's great portfolio in Covid, cancer and non-opioid pain will all be nicely financed with several blockbusters hitting the market this year!
XWAV...Thanks for this item. Very interesting. Stem cells seem to be amongst the leaders in the battle against ARDS. It will be interesting to see which sources are best...or if combinations are synergistic. Meanwhile I'm glad Sorrento gives us exposure to adipose derived stem cells through the PSC licenced trial, and to the post partum placenta derived stem cells of Celularity.
Biden's going to emphasize testing. Hope the CoviStix are ready!
Coronavirus update: Biden calls for 100 million vaccinations, $121 billion for health care to fight COVID-19
Anjalee Khemlani·Senior Reporter
Fri, January 15, 2021, 7:11 AM·
President-elect Joe Biden released a $1.9 trillion COVID-19 response plan on Thursday evening, setting goals for his first 100 days in office, including a call for 100 million vaccinations by then....
Among other efforts focused on economic recovery, the Biden plan envisions at least $121 billion for health care. That includes $20 billion for a national vaccination plan, $50 billion for a testing expansion plan, $30 billion for the Disaster Relief Fund to replenish supplies and activate the National Guard, as well as $10 billion for domestic manufacturing through the Defense Production Act, which President Donald Trump invoked early in the pandemic, though efforts eventually dwindled."
Many who follow Sorrento closely expect important news on 3 programs over next 10 days.
1. ACEA aquisition. Sorrento already has the rights for Abivirtinib outside of China. But the China rights to Abivertinib and worldwide rights to a phase 2 ready lupus drug could be attractive.
2. Interim results of phase 2 trials of Abivirtinib in the US and Brazil in the anti cytokine storm indication. Abivertinib already has some very worthwhile results in Phase 3 against NSCLC and phase 2 against B cell lymphomas. Will it also be useful against cytokine storm caused by Covid, pneumonia , burns etc? Will it receive an EUA?
3. EUA for Covi-Stix in US and Mexico. Low cost, 98/99% accurate, shallow nasal swab test could fill multi-billion worldwide medical need.
Combined with the growing value of the Celularity and ImmunoBio investments and very likely large settlement of PSS lawsuit...Sorrento's great portfolio in Covid, cancer and non-opioid pain will all be nicely financed!
Todays seekingalpha analysis was very superficial and obviously based on the Sorrento September 2020 presentation rather than the much more informative January 2021 presentation. Sorrento is a different company now!
https://investors.sorrentotherapeutics.com/static-files/c7e5a3a2-7849-42e7-b531-2e6a7a7f3e94
Jan.13,2021...H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Sorrento Therapeutics today and set a price target of $30.00. The company’s shares closed last Tuesday at $7.44.
According to TipRanks.com, Selvaraju is a top 100 analyst with an average return of 27.9% and a 69.5% success rate....
Currently, the analyst consensus on Sorrento Therapeutics is a Moderate Buy with an average price target of $30.00.
I'm glad to be exposed to Celularity's great potential through Sorrento's ongoing financial interest. It appears to me that Sorrento added to/or maintained, their interest through participating in recent Celularity fund raises.
Through Sorrento we have an interest in Celularity's PLACENTAL derived stem cells, and through the licence with Personalized Stem Cell in ADIPOSE derived stem cells.
I have no expertise in this area, but will await results with great interest. It's just one more example of the diversification we have with Sorrento's large cancer, Covid and non-opioid pain portfolios!
XWAV....Here's the rationale for the use of adipose stem cells.
Why use adipose sourced stem cells?
"MSCs are abundant in adipose tissue and highly potent. Human ASCs have significant advantages over MSCs derived from other sources because they are obtained from a minimally invasive lipoaspiration procedure [33]. The MSC concentration in adipose is greater than all other tissues in the body [34, 35] and the potency is maintained with age of the donor [36], unlike bone marrow derived MSCs [37, 38]. Significant numbers of ASCs can be obtained due to accessibility to the subcutaneous adipose tissue and the volume that can easily be extracted. Taken together, the ASC has advantages in both autologous use and allogeneic use. Significant antiinflammatory effects have been confirmed in many veterinary and human clinical studies [39–41]."
This is from the following study.
Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients
Christopher J. Rogers1*, Robert J. Harman1, Bruce A. Bunnell2, Martin A. Schreiber3, Charlie Xiang4, Fu-Sheng Wang5, Antonio F. Santidrian6 and Boris R. Minev6,7
Abstract
In late 2019, a novel coronavirus (SARS-CoV-2) emerged in Wuhan, capital city of Hubei province in China. Cases of SARS-CoV-2 infection quickly grew by several thousand per day. Less than 100 days later, the World Health Organiza-tion declared that the rapidly spreading viral outbreak had become a global pandemic. Coronavirus disease 2019 (COVID-19) is typically associated with fever and respiratory symptoms. It often progresses to severe respiratory distress and multi-organ failure which carry a high mortality rate. Older patients or those with medical comorbidi-ties are at greater risk for severe disease. Inflammation, pulmonary edema and an over-reactive immune response can lead to hypoxia, respiratory distress and lung damage. Mesenchymal stromal/stem cells (MSCs) possess potent and broad-ranging immunomodulatory activities. Multiple in vivo studies in animal models and ex vivo human lung models have demonstrated the MSC’s impressive capacity to inhibit lung damage, reduce inflammation, dampen immune responses and aid with alveolar fluid clearance. Additionally, MSCs produce molecules that are antimicrobial and reduce pain. Upon administration by the intravenous route, the cells travel directly to the lungs where the majority are sequestered, a great benefit for the treatment of pulmonary disease. The in vivo safety of local and intravenous administration of MSCs has been demonstrated in multiple human clinical trials, including studies of acute respiratory distress syndrome (ARDS). Recently, the application of MSCs in the context of ongoing COVID-19 disease and other viral respiratory illnesses has demonstrated reduced patient mortality and, in some cases, improved long-term pulmonary function. Adipose-derived stem cells (ASC), an abundant type of MSC, are proposed as a therapeutic option for the treatment of COVID-19 in order to reduce morbidity and mortality. Additionally, when proven to be safe and effective, ASC treatments may reduce the demand on critical hospital resources. The ongoing COVID-19 outbreak has resulted in significant healthcare and socioeconomic burdens across the globe. There is a desperate need for safe and effective treatments. Cellular based therapies hold great promise for the treatment of COVID-19. This literature summary reviews the scientific rationale and need for clinical studies of adipose-derived stem cells and other types of mesenchymal stem cells in the treatment of patients who suffer with COVID-19.Keywords:COVID-19, SARS-CoV-2, ARDS, Pneumonia, Mesenchymal stem cells
I think you'll find a lot of good information on the personsalizedstemcells.com website. Sorrento licenced tha adipose stem cell program from them. PSC intended to start the trial in August 2021. Sorrento has opened one test site and is enrolling patients NOW.
PSC claims adipose stem cells are more easily procured, less likely to be damaged, and are very durable.